=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Page 4

Kateshia Brooks
Otsuka Pharmaceutical Development and Commercialization, Inc.
NDA 205422 / MA 772, 791

explaining any plan for discontinuing use of such communications, or for ceasing distribution
of Rexulti.

If you believe that your product is not in violation of the FD&C Act, please include in your
submission to us your reasoning and any supporting information for our consideration within
15 working days from the date of receipt of this letter.

The concerns discussed in this letter do not necessarily constitute an exhaustive list of
potential violations. It is your responsibility to ensure compliance with each applicable
requirement of the FD&C Act and FDA implementing regulations.

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266.** A courtesy copy can be sent by
facsimile to (301) 847-8444. Please refer to MA 772 and 791 in addition to the NDA number
in all future correspondence relating to this particular matter. All correspondence should
include a subject line that clearly identifies the submission as a Response to Untitled Letter.
You are encouraged, but not required, to submit your response in eCTD format. All
correspondence submitted in response to this letter should be placed under eCTD Heading
1.15.1.6. Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 0596 under NDA 205422. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CBER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Sapna Shah, PharmD
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

{See appended electronic signature page}

Aline Moukhtara, RN, MPH
Team Leader
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

Reference ID: 5270026
